Biocept Company Profile (NASDAQ:BIOC)

About Biocept

Biocept logoBiocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BIOC
  • CUSIP:
Key Metrics:
  • Previous Close: $0.58
  • 50 Day Moving Average: $0.5877
  • 200 Day Moving Average: $0.8402
  • 52-Week Range: $0.49 - $2.76
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.10
  • P/E Growth: -0.0200
  • Market Cap: $14.92M
  • Outstanding Shares: 25,189,000
  • Beta: 2.04
Profitability:
  • Net Margins: -1,466.69%
  • Return on Equity: -764.73%
  • Return on Assets: -196.39%
Debt:
  • Debt-to-Equity Ratio: -6.10%
  • Current Ratio: 1.38%
  • Quick Ratio: 1.24%
Additional Links:
Companies Related to Biocept:

Analyst Ratings

Consensus Ratings for Biocept (NASDAQ:BIOC) (?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $2.57 (333.41% upside)

Analysts' Ratings History for Biocept (NASDAQ:BIOC)
Show:
DateFirmActionRatingPrice TargetDetails
8/31/2016Rodman & RenshawSet Price TargetBuy$2.50View Rating Details
8/3/2016Feltl & Co.DowngradeBuy -> HoldView Rating Details
6/6/2016Roth CapitalInitiated CoverageBuy$1.20View Rating Details
1/10/2016HC WainwrightReiterated RatingBuy$4.00View Rating Details
1/21/2015AegisReiterated RatingBuyView Rating Details
(Data available from 9/25/2014 forward)

Earnings

Earnings History for Biocept (NASDAQ:BIOC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/2/2016Q216($0.22)($0.20)ViewN/AView Earnings Details
5/12/2016Q116($0.23)($0.25)ViewListenView Earnings Details
3/9/2016Q415($0.26)($0.24)$76.00 million$218.00 millionViewN/AView Earnings Details
11/5/2015Q315($0.22)($0.24)$165.00 millionViewN/AView Earnings Details
8/10/2015Q215($0.23)($0.22)$19.25 million$76.77 millionViewListenView Earnings Details
5/12/2015Q115($0.61)($0.37)ViewListenView Earnings Details
3/9/2015Q414($0.88)($0.87)ViewN/AView Earnings Details
11/13/2014($0.82)($0.87)ViewN/AView Earnings Details
8/15/2014($0.67)($0.67)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Biocept (NASDAQ:BIOC)
Current Year EPS Consensus Estimate: $-0.81 EPS
Next Year EPS Consensus Estimate: $-0.54 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.22)($0.22)($0.22)
Q3 20162($0.22)($0.18)($0.20)
Q4 20162($0.20)($0.18)($0.19)
Q1 20171($0.20)($0.20)($0.20)
Q2 20171($0.19)($0.19)($0.19)
Q3 20171($0.18)($0.18)($0.18)
Q4 20171($0.17)($0.17)($0.17)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Biocept (NASDAQ:BIOC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Biocept (NASDAQ:BIOC)
Insider Ownership Percentage: 6.80%
Institutional Ownership Percentage: 4.80%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/4/2016Bruce GerhardtDirectorBuy25,000$1.00$25,000.00View SEC Filing  
5/4/2016Claire ReissMajor ShareholderBuy614,273$1.00$614,273.00View SEC Filing  
2/13/2015David F HaleChairmanBuy40,000$1.25$50,000.00View SEC Filing  
2/13/2015Marsha Alpert ChandlerDirectorBuy2,000$1.25$2,500.00View SEC Filing  
2/13/2015Michael W NallCEOBuy12,000$1.25$15,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Biocept (NASDAQ:BIOC)
DateHeadline
investornewswire.com logoBiocept, Inc. (NASDAQ:BIOC)'s Expectation Of $11.94 In Sales - Investor Newswire (NASDAQ:BIOC)
www.investornewswire.com - September 24 at 8:05 AM
investornewswire.com logoShares Of Biocept, Inc. (NASDAQ:BIOC) Expected To Hit $2.5 - Investor Newswire (NASDAQ:BIOC)
www.investornewswire.com - September 24 at 8:05 AM
prnewswire.com logoBiocept's Proprietary Liquid Biopsy Platform to be Featured at Two ... - PR Newswire (press release) (NASDAQ:BIOC)
www.prnewswire.com - September 23 at 3:18 PM
News IconKeen Investors Find News on Biocept, Inc. (NASDAQ:BIOC) - Duncan Research (NASDAQ:BIOC)
www.duncanindependent.com - September 23 at 3:18 PM
finance.yahoo.com logoBiocept's Proprietary Liquid Biopsy Platform to be Featured at Two Upcoming Molecular Diagnostics Conferences (NASDAQ:BIOC)
finance.yahoo.com - September 23 at 3:18 PM
capitalcube.com logoETF’s with exposure to Biocept, Inc. : September 23, 2016 (NASDAQ:BIOC)
www.capitalcube.com - September 23 at 3:18 PM
News IconUnder the Microscope, Zeroing in at Biocept, Inc. (NASDAQ:BIOC) - Duncan Research (NASDAQ:BIOC)
www.duncanindependent.com - September 22 at 4:00 PM
News IconStock Update: Estimates & Target in Focus for Biocept, Inc. (NASDAQ:BIOC) - Frisco Fastball (NASDAQ:BIOC)
friscofastball.com - September 22 at 8:04 AM
finance.yahoo.com logoGlobal Circulating Tumor Cell Market Key Players - Viatar CTC Solutions Inc., BIOCEPT, INC. (San Diego), Grail Bio ... - Yahoo Finance (NASDAQ:BIOC)
finance.yahoo.com - September 21 at 8:23 AM
News IconPenny Stock Investors Take an Interest in Biocept, Inc. (NASDAQ:BIOC) - Duncan Research (NASDAQ:BIOC)
www.duncanindependent.com - September 21 at 8:23 AM
sg.finance.yahoo.com logoGSK names Emma Walmsley as new chief executive (NASDAQ:BIOC)
sg.finance.yahoo.com - September 20 at 9:06 AM
openpr.com logoIncreased number of pregnancies are driving the Cell-Free DNA (cfDNA) Testing Market growth (NASDAQ:BIOC)
www.openpr.com - September 19 at 8:36 AM
investornewswire.com logoExpected For Biocept, Inc. (NASDAQ:BIOC) Sales Of $11.94 - Investor Newswire (NASDAQ:BIOC)
www.investornewswire.com - September 16 at 3:47 PM
News IconDr. Shilpa Gupta to study liquid biopsy testing in bladder cancers (NASDAQ:BIOC)
www.canindia.com - September 12 at 3:45 PM
investornewswire.com logoBiocept, Inc. (NASDAQ:BIOC) Expects Sales Of $11.94 - Investor Newswire (NASDAQ:BIOC)
www.investornewswire.com - September 10 at 8:34 AM
prnewswire.com logoBiocept to Collaborate with Renowned Clinical Investigator Dr. Shilpa Gupta to Study the Utility of Liquid Biopsy ... - PR Newswire (press release) (NASDAQ:BIOC)
www.prnewswire.com - September 10 at 8:34 AM
smarteranalyst.com logoCompany Update (NASDAQ:BIOC): Biocept Inc to Collaborate with Renowned Clinical Investigator Dr. Shilpa Gupta to ... - Smarter Analyst (NASDAQ:BIOC)
www.smarteranalyst.com - September 9 at 3:45 PM
finance.yahoo.com logoBiocept to Collaborate with Renowned Clinical Investigator Dr. Shilpa Gupta to Study the Utility of Liquid … (NASDAQ:BIOC)
finance.yahoo.com - September 9 at 8:40 AM
publicnow.com logoBiocept to Collaborate with Renowned Clinical Investigator Dr. Shilpa Gupta to Study the Utility of Liquid Biopsy Testing in Bladder and Prostate Cancers (NASDAQ:BIOC)
www.publicnow.com - September 9 at 8:40 AM
News IconWhat are Research Firms Saying About Biocept, Inc. (NASDAQ:BIOC)? - Frisco Fastball (NASDAQ:BIOC)
friscofastball.com - September 8 at 8:16 AM
News IconGlobal Cell-Free DNA Testing Market Driven by Increasing Incidences of Diseases Like Chromosomal Abnormalities (NASDAQ:BIOC)
reports.pr-inside.com - September 6 at 8:39 AM
prnewswire.com logoBiocept Announces Agreement with Teneovita Medical to Market and Distribute its Liquid Biopsy Testing Platform in ... - PR Newswire (press release) (NASDAQ:BIOC)
www.prnewswire.com - September 1 at 3:49 PM
smarteranalyst.com logoRodman & Renshaw Bullish on Biocept Inc (BIOC) Following Fourth International Expansion - Smarter Analyst (NASDAQ:BIOC)
www.smarteranalyst.com - September 1 at 3:49 PM
News IconTeneovita to market & distribute Biocept's liquid biopsy testing services in Canada (NASDAQ:BIOC)
www.pharmabiz.com - September 1 at 12:17 PM
News IconBiocept Expands Chinese Patent Protection Covering Key Technologies for Circulating Tumor Cell Capture and (NASDAQ:BIOC)
www.biomedreports.com - September 1 at 12:17 PM
publicnow.com logoBiocept Expands Chinese Patent Protection Covering Key Technologies for Circulating Tumor Cell Capture and Analysis Used in Liquid Biopsy Tests (NASDAQ:BIOC)
www.publicnow.com - September 1 at 12:17 PM
reuters.com logoBRIEF-Biocept reports agreement with Teneovita Medical - Reuters (NASDAQ:BIOC)
in.reuters.com - August 31 at 3:49 PM
News IconBiocept Inc. Announces Deal With Teneovita for Marketing, Distributing Diagnostic in Canada (NASDAQ:BIOC)
sdbj.com - August 31 at 8:37 AM
reuters.com logoBRIEF-Biocept reports agreement with Teneovita Medical (NASDAQ:BIOC)
www.reuters.com - August 30 at 3:48 PM
streetinsider.com logoBiocept (BIOC) Enters Preferred Provider Agreement with Teneovita Medical (NASDAQ:BIOC)
www.streetinsider.com - August 30 at 3:48 PM
News IconBiocept, Inc. Announces Agreement With To Market And Distribute Its Liquid Biopsy Testing Platform In Canada (NASDAQ:BIOC)
www.biospace.com - August 30 at 3:48 PM
finance.yahoo.com logoBiocept Announces Agreement with Teneovita Medical to Market and Distribute its Liquid Biopsy Testing Platform in Canada (NASDAQ:BIOC)
finance.yahoo.com - August 30 at 8:13 AM
News IconWill Biocept, Inc. (NASDAQ:BIOC) miss earning estimates again ... - The Independent Republic (NASDAQ:BIOC)
theindependentrepublic.com - August 27 at 3:46 PM
live-pr.com logoNew Market Report: Biocept, Inc. (BIOC) - Financial and Strategic SWOT Analysis Review (NASDAQ:BIOC)
www.live-pr.com - August 26 at 3:48 PM
News IconStock's Buzz: Biocept, Inc. (NASDAQ:BIOC), NorthStar Asset Management Group, Inc. (NYSE:NSAM) - Newburg Press (NASDAQ:BIOC)
newburghpress.com - August 24 at 3:50 PM
News IconStocks Trapped in Bearish Claws: EnteroMedics Inc. (NASDAQ:ETRM), Biocept, Inc. (NASDAQ:BIOC) - Street Wise Report (press release) (blog) (NASDAQ:BIOC)
streetwisereport.com - August 24 at 12:04 PM
capitalcube.com logoETF’s with exposure to Biocept, Inc. : August 23, 2016 (NASDAQ:BIOC)
www.capitalcube.com - August 23 at 3:52 PM
investornewswire.com logoWill Biocept, Inc. (NASDAQ:BIOC) Hit $2.5 Price Target? - Investor Newswire (NASDAQ:BIOC)
www.investornewswire.com - August 21 at 8:33 AM
publicnow.com logoBiocept to Present at Next Generation Dx Summit (NASDAQ:BIOC)
www.publicnow.com - August 18 at 12:15 PM
sbwire.com logoReport Published: "Liquid Biopsy Market - Forecast to 2021" (NASDAQ:BIOC)
www.sbwire.com - August 17 at 12:02 PM
finance.yahoo.com logoBIOCEPT INC Financials (NASDAQ:BIOC)
finance.yahoo.com - August 13 at 3:50 PM
capitalcube.com logoETF’s with exposure to Biocept, Inc. : August 12, 2016 (NASDAQ:BIOC)
www.capitalcube.com - August 12 at 4:03 PM
News IconBiocept Inc. Signs Distribution Deal for Philippines (NASDAQ:BIOC)
sdbj.com - August 11 at 9:43 PM
reuters.com logoBRIEF-Biocept expands distribution of liquid biopsy tests to Philippines (NASDAQ:BIOC)
www.reuters.com - August 11 at 12:00 PM
publicnow.com logoBiocept Expands Distribution of Liquid Biopsy Tests to the Philippines (NASDAQ:BIOC)
www.publicnow.com - August 11 at 11:59 AM
capitalcube.com logoBiocept, Inc. :BIOC-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016 (NASDAQ:BIOC)
www.capitalcube.com - August 9 at 4:57 PM
biz.yahoo.com logoBIOCEPT INC Files SEC form 10-Q, Quarterly Report (NASDAQ:BIOC)
biz.yahoo.com - August 5 at 9:13 PM
News IconSan Diego Entrepreneurs Launch Innovative E-Commerce Health Care Company (NASDAQ:BIOC)
cad.digitalmedianet.com - August 4 at 3:57 PM
twst.com logoBiocept Inc.: Biocept Reports 2016 Second Quarter Financial Results (NASDAQ:BIOC)
www.twst.com - August 3 at 9:31 PM
fortune.com logoAnalyst Ratings On Watch List: Biocept Inc (NASDAQ:BIOC ... - Review Fortune (NASDAQ:BIOC)
reviewfortune.com - August 3 at 3:53 PM

Social

Biocept (NASDAQ:BIOC) Chart for Sunday, September, 25, 2016


Last Updated on 9/25/2016 by MarketBeat.com Staff